Dermata Therapeutics, Inc.
DRMA
$1.29
$0.1210.26%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.54M | 1.37M | 1.26M | 1.15M | 1.06M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.93M | 1.90M | 1.76M | 1.77M | 2.34M |
| Operating Income | -1.93M | -1.90M | -1.76M | -1.77M | -2.34M |
| Income Before Tax | -1.85M | -1.86M | -1.69M | -1.70M | -2.30M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.85M | -1.86M | -1.69M | -1.70M | -2.30M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.85M | -1.86M | -1.69M | -1.70M | -2.30M |
| EBIT | -1.93M | -1.90M | -1.76M | -1.77M | -2.34M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.48 | -1.65 | -1.65 | -2.67 | -4.47 |
| Normalized Basic EPS | -0.30 | -1.03 | -1.03 | -1.67 | -2.79 |
| EPS Diluted | -0.48 | -1.65 | -1.65 | -2.67 | -4.47 |
| Normalized Diluted EPS | -0.30 | -1.03 | -1.03 | -1.67 | -2.79 |
| Average Basic Shares Outstanding | 3.86M | 1.13M | 1.03M | 637.80K | 515.50K |
| Average Diluted Shares Outstanding | 3.86M | 1.13M | 1.03M | 637.80K | 515.50K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |